Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 07 symbols : ABBV save search
Worldwide Orphan Drugs Industry to 2027 - Featuring Jazz Pharmaceuticals, Merck & Co and Pfizer Among Others
Published: 2021-10-07 (Crawled : 22:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: 3.76%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 300K
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.7%
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
BMY | $48.64 -0.71% 2.3M
|
Health Technology
|
| O: -0.24%
H: 0.2%
C: -2.73%
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
JAZZ | $108.03 -1.5% 89K
|
Health Technology
|
| O: -0.04%
H: 1.01%
C: -1.78%
BIIB | $202.05 4.59% 1.1M
|
Health Technology
|
| O: -0.11%
H: 0.54%
C: -0.56%
AMGN | News | $273.6 0.02% 370K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
orphan drug drug
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.